Abstract
Disrupted gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of schizophrenia. Reductions in hippocampal GABAergic neurons have been found in schizophrenia, and increased hippocampal perfusion has been described in schizophrenia and in people at clinical high-risk for psychosis (CHRp). We have also found decreases in hippocampal GABAA receptors containing the α5 subunit (GABAARα5) in a well-validated neurodevelopmental rat model of relevance for schizophrenia. Positive allosteric modulation of these receptors in the hippocampus using a specific compound was shown to reverse the behavioural and neurophysiological phenotypes of this model. However, whether GABAARα5 availability is dysregulated in the psychosis spectrum at the regional or network levels is unknown. We addressed this issue by using [11C]Ro15-4513 and positron emission tomography (PET) in 22 individuals at CHRp, 10 people with a first-episode psychosis (FEP) and 23 healthy controls (HC). We quantified GABAARα5 availability in the hippocampus and across the brain, and employed a perturbation covariance method to assess individual molecular covariance deviations in CHRp and FEP groups compared to the HC group. Hippocampal GABAARα5 availability was not significantly different between groups (F(2,50)=0.25, p=0.78). However, network analysis identified significant deviations in GABAARα5 covariance between groups, both across all regions (all p<0.001, pairwise Cohen’s d = 0.07-0.5) and relative to the hippocampus (all p<0.001, pairwise Cohen’s d = 0.01-0.67). These findings suggest that psychosis symptoms are associated with alterations to the brain-wide organisation of the GABAARα5 system, rather than changes at a regional level.
Competing Interest Statement
AAG has received consulting fees from Alkermes, Lundbeck, Takeda, Roche, Lyra, Concert, Newron and SynAgile, and research funding from Lundbeck, Newron and Merck. EAR is a full-time employee of Invicro. MV is named as an inventor on a patent related to the use of dopaminergic imaging in mental Illness (ID: WO/2021/111116). GM has received consulting fees from Boehringer Ingelheim.
Funding Statement
This research was funded in whole, or in part, by the Wellcome Trust & The Royal Society [Sir Henry Dale Fellowship 202397/Z/16/Z to GM]. PBL was in receipt of a PhD studentship funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. AAG received funding from USPHS NIMH MH57440. MV is supported by EU funding within the MUR PNRR National Center for HPC, BIG DATA AND QUANTUM COMPUTING (Project no. CN00000013 CN1), the Ministry of University and Research within the Complementary National Plan PNC DIGITAL LIFELONG PREVENTION - DARE (Project no PNC0000002_DARE), and by Fondo per il Programma Nazionale di Ricerca e Progetti di Rilevante Interesse Nazionale (PRIN, Project no 2022RXM3H7).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study obtained ethical approval from the London/Surrey Research Ethics Committee (17/LO/1130).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
